PURPOSECannabis has been legalized across multiple states over the past decade; however, its use among cancer survivors ...

Results The study included 344 patients who underwent RP with a median follow-up of 4.3 years. Both PathomIQ and Decipher scores were associated with rates of biochemical recurrence-free survival ...

Thromboembolic adverse events are preventable. In a large randomized controlled trial (RCT) of primary thromboprophylaxis with rivaroxaban 10 mg once daily (v placebo) in ambulatory patients with ...

Health care delays (postponement of medical care) are a significant barrier to optimal care for cancer survivors, particularly among adolescent and young adults (AYAs). 1 - 3 Despite overall ...

Among 121 total families with LFS at our institutions, 17 patients from 16 (13%) families diagnosed with LFS had an HM. A literature review found an additional 83 patients with detailed descriptions, ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

JCO invites you to enter our first Art of Oncology Narrative Medicine Contest for early career oncologists. Entries will be accepted through August 31, 2025. Finalists will be judged by a panel of ...

As a cancer of the immune system, lymphoma exhibits clinical features and treatment strategies that differ markedly from those of solid tumors. Lymphoma uniquely exhibits a bimodal age distribution, ...

Patients with pretreated R/M CC were randomly assigned to receive camrelizumab (200 mg intravenously once every 3 weeks) plus famitinib (20 mg orally once daily), camrelizumab, or investigator's ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Older patients with classic Hodgkin lymphoma (cHL) have inferior survival compared with younger patients. We report a subset analysis of older patients (60 years and older) enrolled in the phase three ...

In 2025, ASCO published a guideline update on the use of sentinel lymph node biopsy (SLNB) in patients with early-stage breast cancer (stages I and II) treated with up-front breast-conserving surgery.